Cell Technology, working in collaboration with Dr. Michael Corey, has developed a novel non-radioactive assay to effectively conduct the study with significantly less time compared to radioactive Chromium Release Methods (CR51).
Cell Technology has combined experience of over 30 years in conducting ADCC contract services for our prestigious clients. We provide ADCC/CDC assay services to determine the activity of the antibody and/or complement against specified target cell lines. The result would be a dose-dependent kinetic response of the therapeutic antibody. The assay service includes optimization of E/T ratios, measurement of ADCC / CDC activity at a series of antibody concentrations, at a certain E:T ratio. Correlation data with FACS analysis can be generated upon request.